Related Experiment Video

Updated: May 29, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

The basis for optimising growth with growth hormone usage in children with idiopathic short stature: analysis of data

Michael B Ranke1, Anders Lindberg

  • 1University Children's Hospital, Universitätsklinikum Tübingen, Tübingen, Germany.

Hormone Research in Paediatrics
|September 14, 2011
PubMed

Insights

Growth hormone (GH) treatment can improve adult height in children with idiopathic short stature (ISS). This study identifies which ISS children benefit most from GH therapy for optimal height outcomes.

Area of Science:

  • Pediatric Endocrinology
  • Growth Hormone Therapy
  • Short Stature Research

Background:

  • Idiopathic short stature (ISS) often results in short adult height.
  • Growth hormone (GH) treatment is approved in the US for ISS but debated in Europe.
  • Existing data on GH efficacy in ISS is extensive but requires further categorization.

Purpose of the Study:

  • To identify children with ISS most likely to achieve normal adult height with GH treatment.
  • To determine which ISS patients gain the most height from GH therapy.
  • To provide a basis for discussing effective and cost-efficient GH use in pediatric short stature.

Main Methods:

  • Analysis of published literature on GH treatment for ISS.
  • Review of data from the Pfizer International Growth Study Database (KIGS).
  • Examination of a KIGS survey of 454 patients who reached adult height.

Main Results:

  • Categorization of ISS children based on their potential for height gain with GH treatment.
  • Identification of patient subgroups with the greatest likelihood of achieving normal adult height.
  • Evidence supporting the efficacy of GH treatment in specific ISS populations.

Conclusions:

  • GH treatment offers a viable option for improving adult height in select children with ISS.
  • Further research and data analysis are crucial for optimizing GH treatment strategies.
  • Evidence-based guidelines can enhance the efficacy and cost-effectiveness of GH therapy for pediatric short stature.

More Related Videos

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation09:02

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation

Published on: February 15, 2018

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Polygenic Traits01:18

Polygenic Traits

When more than one gene is responsible for a given phenotype, the trait is considered polygenic. Human height is a polygenic trait. Studies have uncovered hundreds of loci that influence height, and there are believed to be many more. Due to the high number of genes involved, as well as environmental and nutritional factors, height varies significantly within a given population. The distribution of height forms a bell-shaped curve, with relatively few individuals in the population at the...